Index to the Interim Condensed Consolidated Financial Statements
F-2
F-3
F-4
F-6
F-7
F-8
F-1

Interim condensed consolidated statement of profit or loss for the three months ended September 30, 2023 and 2022, and the nine months ended September 30, 2023 and 2022 (unaudited)
For the three months ended September 30,For the nine months ended September 30,
(in €‘000)Notes2023202220232022
Revenue from contracts with customers5
Charging sessions22,036 14,405 73,174 38,399 
Service revenue from the sale of charging equipment523 889 2,009 19,331 
Service revenue from installation services3,451 5,181 13,734 11,145 
Service revenue from operation and maintenance of charging equipment1,073 556 3,329 2,378 
Service revenue from consulting services1,524 1,289 4,571 1,759 
Total revenue from contracts with customers28,607 22,320 96,817 73,012 
Cost of sales
Cost of sales - charging sessions(19,547)(21,304)(57,307)(53,641)
Cost of sales - sale of charging equipment(398)(667)(952)(13,689)
Cost of sales - installation services(2,937)(4,801)(11,574)(7,704)
Cost of sales - operation and maintenance of charging equipment(322)(114)(1,123)(268)
Total cost of sales(23,204)(26,886)(70,956)(75,302)
Gross profit5,403 (4,566)25,861 (2,290)
Other income/(expenses)6(1,508)4,543 2,645 13,530 
Selling and distribution expenses(565)(804)(1,674)(2,501)
General and administrative expenses7(36,653)(15,431)(83,847)(287,084)
Operating loss(33,323)(16,258)(57,015)(278,345)
Finance income/(costs)8(9,907)(4,438)(24,656)10,735 
Loss before income tax(43,230)(20,696)(81,671)(267,610)
Income tax benefit (expense)14112 (802)(393)(963)
Loss for the period(43,118)(21,498)(82,064)(268,573)
Attributable to:
Equity holders of the Company(43,015)(21,356)(81,829)(268,269)
Non-controlling interests(103)(142)(235)(304)
Loss per share attributable to the equity holders of the Company:
Basic and diluted loss per ordinary share9(0.16)(0.08)(0.31)(1.09)
The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F-2

Interim condensed consolidated statement of comprehensive income for the three months ended September 30, 2023 and 2022, and the nine months ended September 30, 2023 and 2022 (unaudited)
For the three months ended September 30,For the nine months ended September 30,
(in €‘000)Notes2023202220232022
Loss for the period(43,118)(21,498)(82,064)(268,573)
Other comprehensive income/(loss)
Items that may be reclassified to profit or loss in subsequent periods
Exchange differences on translation of foreign operations(14)(3)(60)(36)
Income tax related to these items— — — — 
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods, net of tax(14)(3)(60)(36)
Items that may not be reclassified to profit or loss in subsequent periods
Changes in the fair value of equity investments at fair value through other comprehensive income164,649 (2,922)(1,926)(2,922)
Remeasurements of post-employment benefit obligations— 9 — 9 
Income tax related to these items— 88 204 88 
Other comprehensive income/(loss) that may not be reclassified to profit or loss in subsequent periods, net of tax4,649 (2,825)(1,722)(2,825)
Other comprehensive income/(loss) for the period, net of tax4,635 (2,828)(1,782)(2,861)
Total comprehensive income/(loss) for the period, net of tax(38,483)(24,326)(83,846)(271,434)
Attributable to:
Equity holders of the Company(38,380)(24,184)(83,611)(271,130)
Non-controlling interests(103)(142)(235)(304)
The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F-3

Interim condensed consolidated statement of financial position as at September 30, 2023 (unaudited) and December 31, 2022
(in €‘000)NotesSeptember 30, 2023December 31, 2022
Assets
Non-current assets
Property, plant and equipment11157,509 134,718 
Intangible assets1121,404 24,648 
Right-of-use assets63,371 47,817 
Deferred tax assets523 523 
Other financial assets60,505 62,487 
Total non-current assets303,312 270,193 
Current assets
Inventories41,125 26,017 
Prepayments and other assets16,903 9,079 
Trade and other receivables42,835 47,235 
Contract assets896 1,512 
Other financial assets6,469 601 
Cash and cash equivalents28,829 83,022 
Total current assets137,057 167,466 
Total assets440,369 437,659 
Equity
Share capital1232,142 32,061 
Share premium12364,928 365,900 
Reserves(10,075)(6,860)
Accumulated deficit(436,331)(364,088)
Equity attributable to equity holders of the Company(49,336)27,013 
Non-controlling interests510 745 
Total equity(48,826)27,758 
Non-current liabilities
Borrowings13312,160 269,033 
Lease liabilities60,212 44,044 
Provisions and other liabilities768 520 
Contract liabilities925 2,442 
Deferred tax liabilities1,980 2,184 
Total non-current liabilities376,045 318,223 
The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

















F-4


Interim condensed consolidated statement of financial position as at September 30, 2023 (unaudited) and December 31, 2022
(in €‘000)NotesSeptember 30, 2023December 31, 2022
Current liabilities
Trade and other payables53,755 56,390 
Contract liabilities4,776 7,917 
Current tax liabilities705 1,572 
Lease liabilities9,279 7,280 
Provisions and other liabilities7.139,164 17,223 
Warrant liabilities5,471 1,296 
Total current liabilities113,150 91,678 
Total liabilities489,195 409,901 
Total equity and liabilities440,369 437,659 
The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.


F-5

Interim condensed consolidated statement of changes in equity for the nine months ended September 30, 2023 and 2022 (unaudited)
Attributable to ordinary equity holders of the Company
(in €‘000)NotesShare capitalShare premium Reserves Accumulated deficitTotalNon-controlling interestsTotal equity
As at January 1, 20221 61,888 4,195 (142,735)(76,651)— (76,651)
Loss for the nine months— — — (268,269)(268,269)(304)(268,573)
Other comprehensive income/(loss) for the nine months— — (2,861)— (2,861)— (2,861)
Total comprehensive income/(loss) for the nine months— — (2,861)(268,269)(271,130)(304)(271,434)
Other changes in reserves(503)503 — — — 
Equity contribution (Allego Holding shareholders)1228,311 73,620 — — 101,931 — 101,931 
Equity contribution (Spartan shareholders)121,789 85,808 — — 87,597 — 87,597 
Equity contribution (PIPE financing)121,800 130,890 — — 132,690 — 132,690 
Equity contribution (Private warrants exercise)12160 13,694 — — 13,854 — 13,854 
Share-based payment expenses7— — — 81,184 81,184 — 81,184 
Non-controlling interests on acquisition of subsidiary— — — — — 1,259 1,259 
As at September 30, 202232,061 365,900 831 (329,317)69,475 955 70,430 
As at January 1, 202332,061 365,900 (6,860)(364,088)27,013 745 27,758 
Loss for the nine months— — — (81,829)(81,829)(235)(82,064)
Other comprehensive income/(loss) for the nine months— — (1,782)— (1,782)— (1,782)
Total comprehensive income/(loss) for the nine months— — (1,782)(81,829)(83,611)(235)(83,846)
Other changes in reserves— — (1,433)1,433 — — — 
Share-based payment expenses7— — — 8,233 8,233 — 8,233 
Issuance of shares under the LTIP from IPO Grant Shares121 — — — 1 — 1 
Issuance of shares under the LTIP from RSUs1280 — — (80)— — — 
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants12— (972)— — (972)— (972)
As at September 30, 202332,142 364,928 (10,075)(436,331)(49,336)510 (48,826)
The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.
F-6

Interim condensed consolidated statement of cash flows for the nine months ended September 30, 2023 and 2022 (unaudited)
(in €‘000)Notes20232022
Cash flows from operating activities
Cash generated from/(used in) operations10(32,914)(89,640)
Interest paid(13,465)(5,697)
Income taxes paid(813)(343)
Other cash flows from operating activities228 — 
Net cash flows from/(used in) operating activities(46,964)(95,680)
Cash flows from investing activities
Acquisition of Mega-E, net of cash acquired— (3,949)
Acquisition of MOMA, net of cash acquired— (58,643)
Purchase of property, plant and equipment11(48,007)(24,971)
Proceeds from sale of property, plant and equipment11— 12 
Purchase of intangible assets11— (1,241)
Proceeds from investment grants2,381 371 
Other cash flows used in investing activities(113)— 
Net cash flows from/(used in) investing activities(45,739)(88,421)
Cash flows from financing activities
Proceeds from borrowings1343,400 50,000 
Repayment of borrowings— (11,936)
Payment of principal portion of lease liabilities(3,322)(4,067)
Payment of transaction costs on new equity instruments12— (925)
Payment of transaction costs on borrowings13(1,576)— 
Proceeds from issuing equity instruments (Spartan shareholders)— 132,690 
Proceeds from issuing equity instruments (PIPE financing)— 10,079 
Net cash flows from/(used in) financing activities38,502 175,841 
Net increase/(decrease) in cash and cash equivalents(54,201)(8,260)
Cash and cash equivalents at the beginning of the nine months
83,022 24,652 
Effect of exchange rate changes on cash and cash equivalents8 6 
Cash and cash equivalents at the end of the nine months
28,829 16,398 
The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.
F-7

Notes to the unaudited interim condensed consolidated financial statements
Index to notes to the unaudited interim condensed consolidated financial statements
1.
F-9
2.
F-9
2.1
F-9
2.2
F-9
2.3
F-11
2.4
F-12
3.
F-12
3.1
F-12
3.2.
F-12
4.
F-12
5.
F-13
6.
F-14
7.
F-14
7.1
F-14
7.2
F-16
7.3
F-18
7.4
F-20
8.
F-20
9.
F-21
10.
F-22
11.
F-22
12.
F-23
13.
F-24
14.
F-27
15.
F-28
16.
F-29
17.
F-31
18.
F-33
19.
F-33
19.1
F-34
20.
F-35
F-8

1    Reporting Entity
Allego N.V. (“Allego” or the "Company”), a continuation of the former Allego Holding B.V. (“Allego Holding”) as detailed below, was incorporated as a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) on June 3, 2021 under the laws of the Netherlands, under the name of Athena Pubco B.V.
On March 16, 2022, Athena Pubco B.V. changed its legal form from a private limited liability company to a public limited liability company (naamloze venootschap), changed its name to Allego N.V. and entered into the Deed of Conversion containing the Articles of Association of Allego N.V. Allego N.V. consummated the previously announced business combination (“the SPAC Transaction”) with Spartan Acquisition Corp. III (“Spartan”) pursuant to the terms of the business combination agreement (“BCA”) and became a publicly traded company on the New York Stock Exchange (“NYSE”). The new public company — Allego N.V. — trades under the Allego name with the ticker “ALLG”. The Company’s registered seat and head office are in Arnhem, the Netherlands. Its head office is located at Westervoortsedijk 73 KB, 6827 AV in Arnhem, the Netherlands. The Company is registered with the Dutch Trade Register under number 82985537.
The Company’s main activity is enabling electrification through designing, building and the operation of charging solutions for electric vehicles in Europe. The Company services corporate customers with the long-term operation of comprehensive charging solutions. The Company’s goal is to offer the best EV charging experience with end-to-end charging solutions through different charging products (e.g. slow, fast, ultra-fast charging) in combination with our EV Cloud platform and additional service support. Upon completion of the BCA, Allego N.V. underwent a capital restructuring process which resulted in additional shares being issued to Madeleine Charging B.V. (“Madeleine”), an external consulting firm, the Private Investment in Public Entity (“PIPE”) Investors and former Spartan shareholders. The majority of the Allego N.V. shares are held by Madeleine, which is an indirectly controlled subsidiary of Meridiam SAS (“Meridiam”) – a global investor and asset manager based in Paris, France. Meridiam specializes in the development, financing and long-term management of sustainable public infrastructure in the mobility, energy transition and social infrastructure sectors.
These financial statements are the interim condensed consolidated financial statements for the group consisting of Allego N.V. and its subsidiaries (jointly referred to as the “Group” or “Allego Group”).
2    Basis of preparation and changes to the Group's accounting policies
2.1. Basis of preparation
The interim condensed consolidated financial statements for the three months ended September 30, 2023 and the nine months ended September 30, 2023 have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”) and are unaudited.
The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.
The interim condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise stated. All amounts disclosed in the interim condensed consolidated financial statements are presented in thousands of euros (€), unless otherwise indicated.
The interim condensed consolidated financial statements were prepared by the Executive Board and were authorized for issue in accordance with a resolution of the Executive Board on November 28, 2023.
2.2. Going concern assumption and financial position
The accompanying interim condensed consolidated financial statements of the Group have been prepared assuming the Group will continue as a going concern. The going concern basis of presentation assumes that the Group will continue in operation for a period of at least one year after the date these interim condensed consolidated financial statements are issued and contemplates the realization of assets and the settlement of liabilities in the normal course of business. See further discussion below.
The Group’s scale of operations
The Group’s strategy requires significant capital expenditures, as well as investments in building the Group’s organization aimed at increasing the scale of its operations. The Group incurred losses during the first years of its operations including
F-9

the three months ended September 30, 2023 and the nine months ended September 30, 2023 and expects to continue to incur losses in the next twelve months from the issuance date of these interim condensed consolidated financial statements. This is typical in the industry, as builders and operators of EV charging sites often incur losses in the early years of operation as the network grows and consumers begin adopting EVs. Therefore, the Group relies heavily on funding from bank financing and equity issuance. For example, during 2022, the Group expanded its old credit facility by an additional €50 million through an accordion feature with the group of lenders within the original old facility agreement. Additionally, during 2022, the Group entered into a new facility agreement (the "renewed facility") with a group of lenders led by Société Générale and Banco Santander, increasing the total available facility by €230 million to €400 million, to further support its growth. Further envisioned growth — in line with the Group’s strategy — will require additional significant investments from lenders or its existing shareholders.
Financial position of the Group
As of September 30, 2023, the Group had negative equity of €48,826 thousand due to the cumulative impact of losses incurred during its first years of operations (December 31, 2022: positive €27,758 thousand due to the losses incurred during its first years of operations being offset against proceeds from the SPAC Transaction) and cash and cash equivalents of €28,829 thousand (December 31, 2022: €83,022 thousand). The Group's operations to date have been funded by borrowings from the Company's shareholders and banks, as well as proceeds from the SPAC Transaction.
In the interim condensed consolidated statement of financial position as at September 30, 2023, the carrying value of the Group’s borrowings amounts to €312,160 thousand (December 31, 2022: €269,033 thousand). Additionally, the Group had €69,491 thousand in lease liabilities (December 31, 2022: €51,324 thousand) and €53,755 thousand in trade and other payables (December 31, 2022: €56,390 thousand).
Impact of increasing energy prices
The Group provides electricity directly through its own chargers and needs to procure this energy from the power markets in Europe. As a result of the war in Ukraine the price of gas has increased sharply, thereby increasing the demand on the European power markets with corresponding constraints in supply. This supply and demand imbalance has caused record increases in the price of electricity in Europe.
Allego obtains electricity through contracts with power suppliers or through direct sourcing on the power market. Allego utilizes an external, technology-enabled energy management platform to diversify its supply of power. Allego has entered into medium- and long-term power purchase agreements with renewable power to mitigate the future negative impact of increased energy costs. This has allowed the Group to fix the price of a portion of energy purchased, with plans to grow this percentage substantially over the next 6-18 months.
Additionally, the Group expects to be able to pass these costs onto EV customers. The Group increased prices several times during 2022, particularly in the second half of the year in response to rises in the price of electricity, whereas prices decreased during the first nine months of 2023 as a result of a reduction in the price of electricity. Despite the shifts in prices, the Group experienced improved utilization rates, indicating a relatively high degree of demand inelasticity by customers. If energy prices were to decline below the fixed price obtained through power purchase agreements, the Group would still expect to keep prices charged to customers constant, enabling predictable margins on charging revenues.
Financing
On December 19, 2022, the Group entered into the renewed facility with a group of lenders led by Société Générale and Banco Santander, increasing the total available facility by €230,000 thousand to €400,000 thousand, to further support its growth. The renewed facility expires in December 2027 and bears interest at Euribor plus a margin. Under the terms of the renewed facility, the Group is required to comply with financial covenants relating to interest and EBITDA at the consolidated level of Allego N.V. as detailed in Note 13.
Historically the Group met its covenants as per the old facility agreement. A covenant breach would negatively affect the Group’s financial position and cash flows, in a way that could reasonably be expected to influence the decisions of the primary users of these interim condensed consolidated financial statements. The Group considers the likelihood of a breach occurring as higher than remote as the Group incurred losses during the first years of its operations, even though the Group has complied with the covenants of the old facility throughout all reporting periods presented and expects to continue to meet financial covenants performance criteria of the renewed facility.


F-10


In parallel to the renewed facility, the Group entered into two interest rate caps derivatives to help offset the interest rate risk on between 65% and 74% (2022: between 65% and 85%) of the outstanding loan amounts under the renewed facility, with a notional of €237,458 thousand, which mature in December 2027. Interest rate risks on the remaining portion of the outstanding loan amounts, including the impact that higher interest rates would have on the Company’s going concern analysis, was included in the cash flow forecasts described below. Additional information on interest rate risk is described in Note 17.
As at September 30, 2023 the Group has not drawn on €77,390 thousand (December 31, 2022: €120,790 thousand) of this facility.
Liquidity forecasts
Management prepares detailed liquidity forecasts and monitors cash and liquidity forecasts on a continuous basis. In assessing the going concern basis of preparation of the interim condensed consolidated financial statements, management estimated the expected cash flows for the next 12 months, incorporating current cash levels, revenue projections and detailed capital expenditures, operating expenses budget, interest payment obligations, and working capital projections, as well as compliance with covenants, the potential exercise of warrants, potential future equity raises, and availability of other financial funding from banks, like those obtained in 2022. The Group invests in new stations, chargers and grid connections and potential business acquisitions only if the Group has secured financing for such investments. These forecasts reflect potential scenarios and management plans and are dependent on securing significant contracts and related revenues.
The Group has applied different scenarios ranging from a scenario that assumes regular capital expenditure levels based on the current available capex facility and a scenario that assumes a service-light model including revenues based only on existing contracts. All scenarios result in the Group having sufficient available cash and liquidity.
Based on these estimations, management has concluded that Allego will be able to fund the expected cash outflows in the next 12 months. Although the expectation for the coming year is that the Company will continue to make additional investments, its cash flows from operations and renewed credit facility is sufficient for at least the next 12 months from the issuance of these interim condensed consolidated financial statements. Therefore, the interim condensed consolidated financial statements have been prepared under the assumption that the Group operates on a going concern basis.
As described above, long-term investments, development activities, and operations more than 12 months out may require additional financing to be obtained. Currently, no commitments exist for further growth investments. The Group will be required to seek additional financing to continue to execute its growth strategy and business plan in the long-term. The realization of such financing is inherently uncertain. Securing additional funding — by raising additional equity or debt financing — is important for the Group’s ability to continue as a going concern in the long-term. However, there is no assurance that the Group will be able to raise additional equity or debt financing on acceptable terms, or at all.
2.3. Significant accounting policies
The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s consolidated annual financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023, except for the adoption of new standards effective as of January 1, 2023 (refer to Note 2.4), and the adoption of new accounting policies as indicated in this note.
2.3.1 Share-based payments
2.3.1.1 Other share-based payment plans
The share-based payment arrangements in place related to the Long-Term Incentive Plan ("LTIP") qualify as equity settled share-based payments in accordance with IFRS 2. As mentioned in Note 7.3, as part of Allego´s incentive plans, certain eligible members of the board of directors and employees were granted Restricted Stock Units ("RSUs"), performance based share options ("LTIP Performance Options") and Company ordinary shares ("IPO Grant Shares"), based on the Company's internal performance evaluation framework.
The grant date fair value is recognized as an operating expense with a corresponding increase in retained earnings. The fair value is determined at the grant date and the total expense is recognized over the vesting period. At the end of each reporting period, the Group revises the expense for the services received based on the vesting conditions. The impact is
F-11

recognized in the (interim condensed) consolidated statement of profit or loss with the corresponding increase in retained earnings.
The IPO Grant Shares, LTIP Performance Options and RSUs do not include any market conditions or non-vesting conditions that should be included in their fair value. The grant date fair value remains the same over time.
2.4. New accounting standards, interpretations and amendments adopted by the group
A number of amended standards became applicable for the current reporting period as disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022. The Group did not have to change its accounting policies or make retrospective adjustments as these amended standards do not have a material effect on the Group's interim condensed consolidated financial statements:
Furthermore, the following amendments to standards have been published by the IASB. The amendments to IAS 12 are effective as of January 1, 2023. All other amendments will become effective on or after January 1, 2024. These have no material effect on the Group's interim condensed consolidated financial statements:
•Amendments to IAS 21 - Lack of Exchangeability
•Amendments to IAS 7 and IFRS 7 - Supplier Finance Arrangements
•Amendments to IAS 12 - International Tax Reform — Pillar Two Model Rules
•Amendment to IFRS 16 – Leases on sale and leaseback
•Amendments to IAS 1 – Presentation of Financial Statements
3    Significant accounting estimates, assumptions and judgments
The preparation of the Group’s interim condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent assets and liabilities. The reported amounts that result from making estimates and assumptions, by definition, will seldom equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies.
The significant accounting estimates, assumptions and judgments applied in preparing these interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.
3.1. Judgments
In the process of applying the Group’s accounting policies, no significant changes have occurred compared to the judgements disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.
3.2. Estimates and assumptions
In the process of applying the Group’s accounting policies, no significant changes have occurred compared to the estimates and assumptions disclosed in Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.
4    Segmentation
The Executive Board of the Group is the chief operating decision maker (“CODM”) which monitors the operating results of the business for the purpose of making decisions about resource allocation and performance assessment. The management information provided to the CODM includes financial information related to revenue, cost of sales and gross result disaggregated by charging revenue and combined service revenue streams and by region. These performance measures are measured consistently with the same measures as disclosed in the (interim condensed) consolidated financial statements. Further financial information, including net income (loss), employee expenses and operating expenses are only provided on a consolidated basis.
F-12

The CODM assesses the financial information of the business on a consolidated level. As the operating results of the business for the purpose of making decisions about resource allocation and performance assessment are monitored on a consolidated level, the Group has one operating segment which is also its only reporting segment.
As the Group only has one reporting segment, all relevant financial information is disclosed in the interim condensed consolidated financial statements.
Revenue from external customers
The Company is domiciled in the Netherlands. The amount of revenue from external customers, based on the locations of the customers, can be broken down by country as follows:
For the three months ended September 30,For the nine months ended September 30,
(in €‘000)2023202220232022
The Netherlands12,492 9,925 46,475 29,901 
Belgium4,546 2,217 14,201 6,016 
Germany5,071 3,434 15,264 10,041 
France5,394 6,188 18,076 25,327 
Other1,104 556 2,801 1,727 
Total28,607 22,320 96,817 73,012 
5    Revenue from contracts with customers
Disaggregation and timing of revenue from contracts with customers
Set out below is the disaggregation of the Group’s revenue from contracts with customers.
For the three months ended September 30,For the nine months ended September 30,
(in €‘000)2023202220232022
Type of goods or service
Charging sessions22,036 14,405 73,174 38,399 
Service revenue from the sale of charging equipment523 889 2,009 19,331 
Service revenue from installation services3,451 5,181 13,734 11,145 
Service revenue from operation and maintenance of charging equipment1,073 556 3,329 2,378 
Service revenue from consulting services1,524 1,289 4,571 1,759 
Total revenue from external customers28,607 22,320 96,817 73,012 
Timing of revenue recognition
Services transferred over time6,048 7,026 21,634 15,282 
Goods and services transferred at a point in time22,559 15,294 75,183 57,730 
Total revenue from external customers28,607 22,320 96,817 73,012 
F-13

6    Other income/(expenses)
For the three months ended September 30,For the nine months ended September 30,
(in €‘000)2023202220232022
Government grants92 320 277 320 
Income from sale of CO2 tickets
1,728 4,106 5,851 8,979 
Net gain/(loss) on disposal of property, plant and equipment(4,784)1 (5,365)1 
Sublease rental income50 46 150 150 
Fair value gains/(losses) on derivatives (purchase options)— — — 3,856 
Fair value gains/(losses) on pref. shares derivatives— 34 — 34 
Other items1,406 36 1,732 190 
Total(1,508)4,543 2,645 13,530 
Other items
Other items primarily consist of reimbursements that the Group has received from one of its suppliers for chargers.
During the year ended December 31, 2022, the Group purchased a number of chargers that malfunctioned and the Group has disposed of these chargers. As disclosed in the table above, the Group recognized a loss on disposal during the three and nine months ended September 30, 2023. In July 2023, a settlement has been reached with a supplier for damages caused. As a result, the Group has recognized a gain of €1,400 thousand for reimbursement received from suppliers (nine months ended September 30, 2022 and three months ended September 30, 2022: € nil).
7    Share-based payments
7.1. Second Special Fees Agreement
On February 25, 2022, the then immediate parent entity of Allego Holding — Madeleine — entered into a second Special Fees Agreement (the “Second Agreement”) with the same external consulting firm as for the First Agreement described in Note 11.1 of the consolidated financial statements for the year ended December 31, 2022. The purpose of this Second Special Fees Agreement is to compensate the external consulting firm for their continuous strategic and operational advice, as well as support with regards to Allego’s fundraising efforts in the near future. The Agreement ultimately expires on the earlier of June 30, 2025, and the date on which Madeleine would no longer hold any equity security in Allego. As consideration for the Second Special Fees Agreement, the external consulting firm is entitled to receive cash compensation based on the value of the Group in connection with any new injection of equity, whether in cash or in kind, in any entity of the Group subsequent to the Business Combination (each an “Equity Injection”).
On March 10, 2022, the Second Special Fees Agreement was amended to modify the formula of the relevant percentage used in the determination of the fees payable (the “Relevant Percentage”) for equity injections subsequent to the first Equity Injection.
The Group accounts for the Second Special Fees Agreement as a share-based payment since the Group obtained services from the consulting firm in exchange for cash amounts based on the equity value of the Company. Madeleine, instead of the Group, had the obligation to settle the share-based payment arrangement with the consulting firm. The Second Agreement was therefore classified as an equity-settled share-based payment arrangement. On April 20, 2022, the Second Special Fees Agreement was novated from Madeleine to Allego (the “Novation”), with all the other terms of the Second Special Fees Agreement remaining the same. As a result of the Novation, Allego has now the obligation, instead of Madeleine, to settle the share-based payment arrangement with the consulting firm. The Second Special Fees Agreement’s classification therefore changed to a cash-settled share-based payment arrangement from the Novation date.
Certain directors of the Company are entitled to compensation from the external consulting firm in the form of a fixed percentage of the total benefits that the external consulting firm will generate under the Second Special Fees Agreement, including any amendments. The share-based payment expenses for the Second Special Fees Agreement therefore reflect both compensation for external consulting services and key management remuneration.
F-14


Measurement of fair value as an equity-settled plan
In accordance with IFRS 2 Share-based Payment, the fair value of key management remuneration under an equity-settled share-based payment arrangement is measured by reference to the fair value of the equity instruments granted, measured at the grant date. The fair value determined at the grant date is not subsequently adjusted.
As the value of the services provided by the consulting firm is not directly related to the time incurred by the consultants, management considers that the fair value of the services cannot be measured reliably. Therefore, the fair value of the services received under the Second Special Fees Agreement are measured by reference to the fair value of the share-based payment arrangement offered as consideration, as the Group obtains these services. The Group applies an approach where the average fair value over the reporting period is used to determine the fair value of the services received.
Since the Second Special Fees Agreement includes an implicit service condition, the services received under the Second Special Fees Agreement are recognized as expenses over the period in which the Company expects to have the Equity Injections, therefore between February 25, 2022 (the “grant date”) and the dates of the Equity Injections by reference to the fair value of the share-based payment arrangement measured at the grant date (for key management remuneration) or the average fair value over the reporting period (for external consulting services).
Measurement of fair value as a cash-settled plan
Following the Novation, the Second Special Fees Agreement was classified as a cash-settled plan as opposed to an equity-settled plan. Therefore, in accordance with IFRS 2 Share-based Payment, the fair value of both the key management remuneration and the services provided by the consulting firm under a cash-settled share-based payment arrangement is measured by reference to the fair value of the share-based payment arrangement offered as consideration, as the Group obtains these services. The fair value of the liability is recognized over the service period.
In effect, IFRS 2 Share-based Payment provides that the cumulative amount recognized as the expense over the life of the Second Special Fees Agreement is the grant-date fair value plus or minus any subsequent changes in fair value after the change in classification. Therefore, the cumulative amount may be less than the original grant-date fair value.
Fair value of equity instruments granted
The fees payable under the Second Special Fees Agreement will depend on the future value of the Allego Group following each future Equity Injection. Since there is no market price for the services, to measure the fair value of this instrument under IFRS 2 Share-based Payment, the future value of the Allego Group for the Equity Injections has been derived from a weighted average valuation model in which that value can be simulated based on various amounts and expected dates of Equity Injection events, and taking into account the likelihood of Equity Injections to happen, as well as the expected price per share upon Equity Injection.
The total fair value of the share-based payment arrangement as at September 30, 2023 is estimated at €49,958 thousand (grant date: €32,250 thousand). The increase in fair value of the share-based payment arrangement is mainly driven by an increase in the probability and expected amount of the Equity Injection events.
The Group assessed the impact to the fair value of the share-based payment arrangement as a result of the amendment to the Second Special Fees Agreement which was entered into in March 2022. The amendment modifies the formula of the Relevant Percentage applied to the future value of the Group for equity injections subsequent to the first Equity Injection, which is a component of the calculation of the fees payable. However, the Relevant Percentage used to calculate the fees remained the same following the amendment and therefore did not impact the fair value of the Second Special Fees Agreement as of the amendment date.
Additionally, the Group assessed the accounting impact of the Novation. The Group measured the liability using the Novation date fair value of the equity-settled shared-based payment arrangement based on the elapsed portion of the vesting period (period from Grant Date to each Equity Injection date). Therefore, as of the Novation, an amount of €4,440 thousand was recognized as a current liability, and an amount of €1,353 thousand was recognized as a non-current liability, with a corresponding decrease to equity of €5,793 thousand.
The Group recognized a share-based payment provision related to the Second Special Fees Agreement of €38,357 thousand as of September 30, 2023 (December 31, 2022: €16,806 thousand), included in the current liabilities in the interim condensed consolidated statement of financial position.

F-15


Share-based payment expenses
During the three months ended September 30, 2023, the Group recognized total share-based payment expenses with respect to the Second Special Fees Agreement of €15,028 thousand (three months ended September 30, 2022: gain of €421 thousand). As the share-based payment expenses for the Second Special Fees Agreement reflect both compensation for external consulting services and key management remuneration, the Group has recognized share-based payment expenses for an amount of €9,843 thousand (three months ended September 30, 2022: gain of €276 thousand) as legal, accounting and consulting fees and share-based payments expenses for an amount of €5,185 thousand (three months ended September 30, 2022: gain of €145 thousand) has been recognized as employee benefits expenses, both within general and administrative expenses.
During the nine months ended September 30, 2023, the Group recognized total share-based payment expenses with respect to the Second Special Fees Agreement of €21,551 thousand (nine months ended September 30, 2022: €2,187 thousand). As the share-based payment expenses for the Second Special Fees Agreement reflect both compensation for external consulting services and key management remuneration, the Group has recognized share-based payment expenses for an amount of €14,116 thousand (nine months ended September 30, 2022; €1,752 thousand) as legal, accounting and consulting fees and share-based payments expenses for an amount of €7,435 thousand (nine months ended September 30, 2022: €435 thousand) has been recognized as employee benefits expenses, both within general and administrative expenses.
During the nine months ended September 30, 2022, the Second Special Fees Agreement was modified from equity-settled plan to cash-settled plan as a result of the Novation. The Group recognized share-based payments expenses of €6,380 thousand for the period before the Novation, with a corresponding increase in retained earnings. This amount was split into legal, accounting and consulting fees of €4,498 thousand and employee benefits expenses of €1,882 thousand. For the period after the Novation, the Group recognized a gain on the share-based payments of €4,193 thousand with a corresponding decrease in liability. This amount consisted of a gain of €2,747 thousand recognized in legal, accounting and consulting fees and a gain of €1,446 thousand recognized in employee benefits expenses.
7.2. Management incentive plan
The establishment of the Company’s MIP was approved by the board of directors on April 20, 2022. The MIP is designed to provide long-term incentives for key management employees to deliver long-term shareholder returns, and includes two types of granted options: the right to acquire a percentage of the Company's issued share capital immediately following the listing, subject to the expiry of a blocking period of 18 months (the “MIP Grant Options”), and the right to acquire a percentage of the Company's issued share capital immediately following the listing, subject to predefined performance conditions and the expiry of the blocking period (the “MIP Performance Options”). The granted options carry no dividend or voting rights. The options do not include any market conditions or non-vesting conditions that should be included in the fair value at recognition.
Under the plan, the MIP Grant Options vest immediately, and the MIP Performance Options only vest if certain performance standards are met. Participation in the plan is at the board of directors’ discretion, and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.
The amount of MIP Performance Options that will vest depends on the group’s performance, including operational EBITDA, financing targets, compliance and reporting, engagement with investors, and the minimum service period of the employees. Once vested, the granted options remain exercisable for a period of ten years following the end of the blocking period, which ended on September 18, 2023 for the MIP Grant Options and ten years from the grant date (May 14, 2022) for the MIP Performance Options.
In April 2023, one non-market performance condition included in the original MIP agreement was modified, together with their respective service periods, to be applied to the group's performance over financial year 2023 instead of 2022. For the MIP performance options the blocking period was extended to April 30, 2024. The exercise period is ten years following the end of the blocking period. The exercise period and blocking period end date remain unchanged for the other MIP Performance Options. These changes result in an increased number of awards being expected to vest but do not have an impact on the fair value of the options.
The exercise price of the granted options under the plan is €0.12 per option. When exercisable, each option is convertible into one ordinary share of the Company.

F-16


Set out below are summaries of MIP Grant Options and MIP Performance Options granted under the plan:
20232022
Average exercise price per share option (in €)Number of MIP Grant OptionsNumber of MIP performance optionsAverage exercise price per share option (in €)Number of MIP Grant OptionsNumber of MIP Performance Options
As at January 10.12 1,329,213 1,329,213 — — — 
Granted during the period— — — 0.12 1,329,213 1,329,213 
Exercised during the period— — — — — — 
Forfeited during the period— — — — — — 
As at September 300.12 1,329,213 1,329,213 0.12 1,329,213 1,329,213 
Vested and exercisable at September 300.12 1,329,213 996,910 — — — 
As of September 30, 2023, 1,329,213 MIP Grant Options and 996,910 MIP Performance Options vested and became exercisable after the end of the blocking period, which ended on September 18, 2023. No options expired and no options were exercised during the period ended September 30, 2023.
Share options outstanding at the end of the reporting period have the following expiry dates and exercise prices:

OptionsGrant dateExpiry dateExercise price (in €)Share options
September
 30, 2023
MIP Grant OptionsMay 14, 2022September 17, 20330.12 1,329,213 
MIP Performance OptionsMay 14, 2022May 13, 20320.12 996,910 
MIP Performance Options (modified)May 14, 2022April 29, 20340.12332,303 
Total2,658,426 
The weighted average remaining contractual life of options outstanding at the end of period is 9.54 years.
For the three months ended September 30, 2023, the total expenses arising from the MIP transactions recognized during the period as part of employee benefit expense was €1,612 thousand (three months ended September 30, 2022: €1,200 thousand). This includes an amount of €489 thousand (three months ended September 30, 2022: € nil) related to the additional expense recognized as a result of the modification of the MIP agreement.
For the nine months ended September 30, 2023 the total expenses arising from the MIP transactions recognized during the period as part of employee benefit expense was €5,110,682 (nine months ended September 30, 2022: €12,976,086). This includes an amount of €1,444 thousand (nine months ended September 30, 2022: € nil ) related to the additional expense recognized as a result of the modification of the MIP agreement.
Fair value of options granted
The assessed fair value of options was €7.75 per option (September 30, 2022: €7.75) for both the MIP Grant Options and MIP Performance Options.
The fair value was determined as the share price of the Company’s ordinary shares on grant date of $8.17 (€7.871), determined as the closing price on May 13, 2022 (the last working day preceding the grant date), less the exercise price of €0.12.
No specific option-pricing model (e.g., Black-Scholes) was applied for the valuation, as in the situation when the exercise price applicable to the options is negligible, the calculated fair value of an option is close (or equal) to the value of an ordinary share less the exercise price, regardless of the other input parameters applied in the option valuation.
1 Translated at the EUR/USD exchange rate as at May 13, 2022.
F-17

As the options do not include any market conditions or non-vesting conditions that has an impact on the fair value and there is no adjustment for dividends, the grant date fair value of both MIP Grant Options and MIP Performance Options was determined using the same approach.
7.3. Long-term Incentive Plan
The Allego board of directors and the compensation committee approved the general framework for the LTIP on 16 March 2022. The purpose of the LTIP is to provide eligible directors and employees the opportunity to receive stock-based incentive awards for employee motivation and retention and to align the economic interests of such persons with those of Allego’s shareholders. The delivery of certain shares or other instruments under the LTIP to directors and key management are agreed and approved in certain Allego board of directors meetings. On December 20, 2022, the Allego board of directors approved a detailed plan for the LTIP for future years.
Performance Based Share Options
As it relates to the LTIP for Allego executive officers, performance based share options may be granted annually and would be exercisable after a contractual vesting period of two to three years. The number of LTIP Performance Options issued under the LTIP in 2023 is based on four equally-weighted performance criteria: revenue, operational EBITDA, renewable GWh delivered, and appreciation at the discretion of the board of directors. The targets for the performance criteria are set annually.
During the nine months ended September 30, 2023, LTIP Performance Options were granted to executive officers based on 2022 and (expected) 2023 year-end company performance. The LTIP Performance Options related to performance in financial year 2022 have a contractual vesting period of two years, and the number of options awarded was determined in line with the level of completion of the performance criteria for that financial year. In addition, Allego granted LTIP Performance Options with a contractual vesting period of three years and subject to company performance in financial year 2023. This estimated number may be adjusted in the next reporting period depending on the completion of the performance criteria.
The exercise price of the LTIP Performance Options granted under the LTIP is €0.12 per option. When exercised, each LTIP Performance Option is convertible into one ordinary share of the Company.
Set out below is a summary of LTIP Performance Options granted under the plan:
2023
Average exercise price per LTIP Performance Option (in €)Number of LTIP Performance Options
As at January 1— — 
Granted during the period0.12 3,059,955 
Exercised during the period— — 
Forfeited during the period— — 
As at September 300.12 3,059,955 
Vested and exercisable at September 30— — 
During the nine months ended September 30, 2023, the Company granted two types of LTIP Performance Options: 1,039,222 options based on actual 2022 company performance and 2,020,733 options with vesting based on 2023 company performance. The number of options based on 2022 company performance is final, subject to meeting the service condition of two years. The number of options based on 2023 company performance is estimated and will be adjusted, if necessary, based on the actual performance.

LTIP Performance Options outstanding at the end of the reporting period have the following expiry dates and exercise prices:
F-18

OptionsGrant dateVesting dateExpiry dateExercise price (in €)Number of options
September
 30, 2023
LTIP Performance Options (2022)April 12, 2023April 12, 2025April 12, 20320.12 1,039,222 
LTIP Performance Options (2023)January 1, 2023April 12, 2026April 12, 20330.12 2,020,733 

The weighted average remaining contractual life of LTIP Performance Options outstanding at the end of period is 9.65 years.
The total expense arising from the LTIP Performance Options recognized during the three months ended September 30, 2023 as part of employee benefit expense was €1,644 thousand (three months ended September 30, 2022: € nil). For the nine months ended September 30, 2023, the total expense arising from the LTIP Performance Options recognized as part of employee benefit expense was €1,742 thousand (nine months ended September 30, 2022: €nil).
Fair value of LTIP Performance Options granted
The assessed fair value of LTIP Performance Options 2022 was €1.83 per option (September 30, 2022: no options granted). This fair value was determined as the share price of the Company’s ordinary shares on grant date of $2.13 (€1.952), determined as the closing price on April 12, 2023 (the grant date), less the exercise price of €0.12.
The assessed fair value of LTIP Performance Options 2023 was €2.82 per option (September 30, 2022: no options granted). This fair value was determined as the share price of the Company’s ordinary shares on grant date of $3.14 (€2.943), determined as the closing price on December 30, 2022 (the last working day preceding the grant date), less the exercise price of €0.12.
As the LTIP Performance Options do not include any market conditions or non-vesting conditions that have an impact on the fair value and there is no adjustment for dividends, the grant date fair value of LTIP Performance Options was determined using the same approach as used for the options granted under the MIP.
Restricted Stock Units
As it relates to the LTIP for other Allego employees, individuals may elect to receive up to 50% of their annual performance bonus to be paid in RSUs, which would vest on an annual basis. Additionally, certain Allego employees are eligible to receive additional RSUs based on the Company's existing internal performance evaluation framework. These RSUs would be granted annually and vest after three years. In May 2023, the Group awarded RSUs to eligible and selected employees based on the Company's internal performance evaluation framework. The RSUs have a vesting period of three years and are subject to the participant's continued employment until the vesting date.
Under the terms of the same plan, RSUs were awarded to eligible members of the board of directors in May 2023. These RSUs were not subject to any vesting conditions and vested fully on the grant date. The Company's ordinary shares were issued to the eligible members of the board of directors on August 10, 2023.
Set out below are summaries of the number of RSUs granted under the plan:
2023
EmployeesEligible directors
As at January 1— — 
Granted during the period189,201 666,968 
Forfeited during the period— — 
Vested and issued during the period— (666,968)
As at September 30189,201 — 
Vested and exercisable at September 30— — 
2 Translated EUR/USD exchange rate as at 12 April 2023
3 Translated at the EUR/USD rate as at 30 December 2022
F-19

Fair value of RSUs granted
The grant date fair value of the RSUs granted to the employees in 2023 is recognized as an expense on a straight-line basis over the three-year vesting period, with a corresponding entry in equity. Since the RSUs granted to certain members of the board of directors are not subject to any vesting conditions, the grant date fair value of these awards is recognized immediately, on the grant date, as an expense with a corresponding entry in equity.
The assessed fair value of RSUs granted during the period ended September 30, 2023, was €1.97 per option (September 30, 2022: no RSUs granted). The fair value of the RSUs has been determined with reference to the share price of the Company’s ordinary shares at the grant date. Since the Company does not expect to pay dividends during the vesting period, the weighted average fair value of the RSUs granted in the nine months ended September 30, 2023 of $2.13 (€1.974) is equal to share price at the grant date, May 24, 2023.
The share-based payment expense recognized for the three months ended September 30, 2023 for the equity-settled RSUs amounted to €31 thousand (three months ended September 30, 2022: € nil), and only represented the expense in relation to the RSUs issued to employees.
The share-based payment expense recognized for the nine months ended September 30, 2023 for the equity-settled RSUs amounted to €1,361 thousand (nine months ended September 30, 2022: € nil), consisting of €1,317 thousand related to the fully vested board of directors' RSUs recognized on grant date and €44 thousand representing the expense for the current period in relation to the RSUs issued to employees.
IPO Grant Shares
In May 2023, the Group awarded 100 ordinary shares per employee to a select group of individuals who were instrumental in the success of the IPO. The Company granted this one-off share award as of the IPO date to employees of the Company, who were still employed by the Company a year later. This award granted in 2023 was not subject to any vesting conditions. The Company awarded a total number of 9,600 ordinary shares in May 2023. The ordinary shares were issued to the employees on June 9, 2023.
The fair value of the share awards of $2.13 (€1.972) is equal to the share price of the Company's ordinary shares at the date of grant. The share-based payment expenses for the three months ended September 30, 2023 is € nil (three months ended September 30, 2022: € nil) and for the nine months ended September 30, 2023 is €19 thousand (nine months ended September 30, 2022: € nil).

7.4. SPAC Transaction
During the nine months ended September 30, 2022, the Group incurred share-based payment expenses of €158,714 thousand recognized within general and administrative expenses related to the SPAC Transaction, representing the difference between Spartan's net asses at the closing date and the fair value of the Company's shares exchanged in the transaction to Spartan. This difference is considered as an expense representing the costs of service in respect of the stock exchange listing for Spartan's shares.
4 Translated at the EUR/USD exchange rate as at 24 May 2023
F-20

8    Finance income/(costs)
For the three months ended September 30,For the nine months ended September 30,
(in €‘000)2023202220232022
Interest expenses on shareholder loans— — — (1,755)
Interest expenses on old facility— (3,392)— (8,048)
Loss on modification of old facility— (1,730)— (1,730)
Interest expenses on renewed facility(6,471)— (17,284)— 
Finance costs on borrowings(6,471)(5,122)(17,284)(11,533)
Interest expenses on lease liabilities(1,017)(689)(2,473)(1,155)
Fair value gains/(losses) on derivatives(122)2,847 (529)4,907 
Fair value gains/(losses) on public warrant liabilities(1,762)343 (4,175)14,889 
Fair value gains/(losses) on private placement warrant liabilities— — — 7,139 
Exchange differences – net(535)(1,817)(195)(3,512)
Finance income/(costs)(9,907)(4,438)(24,656)10,735 
9    Loss per share
Basic loss per share is calculated by dividing the loss for the period attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.
The following table reflects the loss and share data used in the basic and diluted loss per share calculations for the three months ended September 30, 2023 and 2022, and the nine months ended September 30, 2023 and 2022:
For the three months ended September 30,For the nine months ended September 30,
2023202220232022
Loss attributable to ordinary equity holders of the Company (in €‘000)(43,015)(21,356)(81,829)(268,269)
Weighted average number of ordinary shares for basic and diluted loss per share267,564,249267,177,592267,308,676246,129,260
Basic and diluted loss per share (in €'000)(0.16)(0.08)(0.31)(1.09)
The Company only has ordinary shares. Refer to Note 12 for details about the Company’s share capital.
There is no difference between basic and diluted loss per share as the effect of the potential ordinary shares that would be issued by the Company under the Management Incentive Plan, the Long Term Incentive Plan, or the Public Warrants is anti-dilutive for all periods presented. Refer to Note 7.2 and 7.3 for details on the Management Incentive Plan and the Long Term Incentive Plan, and refer to Note 27 of the consolidated financial statements for the year ended December 31, 2022 for details on the Public Warrants.
Ordinary shares were issued after the reporting date in relation to the exchange of Public Warrants as disclosed in Note 20. There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorization of these interim condensed consolidated financial statements.
F-21

10    Cash generated from operations
For the nine months ended September 30,
(in €‘000)Notes20232022
Loss before income tax(81,671)(267,610)
Adjustments to reconcile loss before income tax to net cash flows:
Loss on modification of old facility— 1,730 
Fair value (gains)/losses on derivatives— (3,890)
Fair value (gains)/losses on Public and Private warrant liabilities4,175 (22,028)
Other finance (income)/costs20,545 9,563 
Share-based payment expenses729,784 241,497 
Depreciation, impairments and reversal of impairments of property, plant and equipment15,216 11,383 
Depreciation and impairments of right-of-use of assets6,061 4,860 
Amortization and impairments of intangible assets3,244 3,589 
Net (gain)/loss on disposal of property, plant and equipment5,064 183 
Movements in working capital:
Decrease/(increase) in inventories(15,108)(19,903)
Decrease/(increase) in other financial assets(6,336)12,257 
Decrease/(increase) in trade and other receivables, contract assets and prepayments and other assets(3,429)(29,139)
Increase/(decrease) in trade and other payables and contract liabilities(11,097)(32,039)
Increase/(decrease) in provisions and other liabilities638 (93)
Cash generated from/(used in) operations(32,914)(89,640)
11    Property, plant and equipment, intangible assets and goodwill
(in €‘000)Property, plant and
equipment		Intangible assets
(excl. goodwill)    		Goodwill    
Carrying amount at December 31, 2022134,718 13,924 10,724 
Movements in the nine months ended September 30, 2023
Additions43,070 — — 
Disposals(9,691)— — 
Depreciation and amortization(15,444)(3,244)— 
Accumulated depreciation and amortization of disposals4,628 — — 
Impairments(321)— — 
Reversal of impairments549 — — 
Carrying amount at September 30, 2023157,509 10,680 10,724 
Investments and disposals of property, plant and equipment
During the nine months ended September 30, 2023, investments in property, plant and equipment amounted to €43,070 thousand (September 30, 2022: €116,590 thousand) and disposals of property, plant and equipment amounted to €5,063 thousand (September 30, 2022: €196 thousand). The disposals during the nine months ended September 30, 2023 mainly relate to chargers purchased by the Group during the year ended December 31, 2022, that malfunctioned and were disposed, refer to Note 6 for further details.
F-22

Impairments and reversals of impairments of chargers
During the three months ended September 30, 2023, the Group recorded an impairment loss of €85 thousand (three months ended September 30, 2022: €133 thousand) and a reversal of impairment of €218 thousand (three months ended September 30, 2022: €270 thousand).
During the nine months ended September 30, 2023, the Group recorded an impairment loss of €321 thousand (nine months ended September 30, 2022: €678 thousand) and a reversal of impairment of €549 thousand (nine months ended September 30, 2022: €392 thousand).
Purchase commitments
The Group’s purchase commitments for chargers and charging infrastructure are disclosed in Note 18. At the end of each reporting period presented, the Group did not have purchase commitments for other asset classes of property, plant and equipment.
12    Share capital, share premium and transaction costs on new equity instruments
Share capital
As at September 30, 2023, the issued share capital of the Company amounts to €32,142 thousand (December 31, 2022: 32,061 thousand), divided into 267,854,160 ordinary shares of €0.12 per share (December 31, 2022: 267,177,592 ordinary shares of €0.12 per share). They entitle the holders to participate in dividends, and to share in the proceeds of winding up the Company in proportion to the number of shares held. The authorized share capital of the Company as at September 30, 2023 amounted to €108,000 thousand (December 31, 2022: €108,000 thousand), divided into 900,000,000 ordinary shares of € 0.12 per share (December 31, 2022: 900,000,000 ordinary shares of € 0.12 per share).
Issuance of ordinary shares related to the IPO Grant Shares award under the LTIP
On June 9, 2023, 9,600 ordinary shares, with a nominal value of €0.12 per share, were issued for no consideration to employees of the Company. These shares relate to the IPO Grant Shares award under LTIP as described in note 7.3.
Issuance of ordinary shares related to the RSUs award under the LTIP
On August 10, 2023, 666,968 ordinary shares, with a nominal value of €0.12 per share, were issued for no consideration to eligible members of the board of directors. These shares relate to the RSUs award under the LTIP as described in note 7.3.
Transaction costs for the future issuance of ordinary shares in exchange of Public Warrants
During the nine months ended September 30, 2023, the Group incurred transaction costs of €972 thousand (nine months ended September 30, 2022: € nil) that are directly attributable to the future issuance of ordinary shares in relation to the exchange of Public Warrants. These transaction costs have been recorded as a deduction to share premium. For further details on the exchange of Public Warrants, refer to Note 20.
Share capital and share premium movements
Movement of share capital and share premium are as follows:
F-23

NotesSharesPrice per share (in €)Share Capital (in €'000)Share Premium (in €'000)
As at January 1, 2022100 1.00 — 61,888 
Immediately prior to the Allego Holding and Spartan Acquisition Corp. III merger (“the SPAC Transaction”)
Shareholder loan equity conversion March 16, 2022
2 1.00 — 101,931 
E8 Special Fee Arrangement March 16, 2022
22 1.00 — — 
As at March 16, 2022 immediately prior to the closing of the SPAC Transaction
124 1.00 — 163,819 
Resulting from the Allego Holding and Spartan Acquisition Corp. III merger (“the SPAC Transaction”)
Elimination old shares March 16, 2022
(124)1.00 — — 
Share Capital increase on conversion March 16, 2022235,935,061 0.12 28,312 (28,311)
Share Capital Spartan March 16, 2022
14,907,582 0.12 1,789 85,808 
Share Capital for PIPE March 16, 2022
12,500,000 0.12 1,500 108,515 
Share Capital for PIPE March 22, 2022
2,500,000 0.12 300 22,375 
Other equity movements in the nine months ended September 30, 2022
Private warrants exercise April 15, 20221,334,949 0.12160 13,694 
As at September 30, 2022267,177,592 0.1232,061 365,900 
As at January 1, 2023267,177,592 0.1232,061 365,900 
Issuance of shares under the LTIP from IPO Grant Shares June 9, 20239,600 0.121 — 
Issuance of shares under the LTIP from RSUs August 10, 2023666,968 0.1280 — 
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants— — — (972)
As at September 30, 2023267,854,160 0.1232,142 364,928 

All the shares issued have been fully paid at the date of the capital issuance.
13    Borrowings
This note provides a breakdown of borrowings in place as at September 30, 2023 and December 31, 2022.
(in €‘000)Interest rateMaturitySeptember 30,
2023		December 31,
2022
Renewed facility
Euribor* + 3.9%**
December 19, 2027312,160 269,033 
Total312,160 269,033 
*The Euribor rate (6M) is floored at 0%. This floor is closely related to the contract of the loan and is therefore not presented separately in the interim condensed consolidated statement of financial position.
**The margin of 3.9% will increase by 0.2% per year, for the first time in December 2025.
F-24

Refinancing of the old facility with the renewed facility
On December 19, 2022, the Group has entered into a new facility agreement (“the renewed facility”) with a group of lenders led by Société Générale and Banco Santander, increasing the total existing available facility ("the old facility") by €230,000 thousand to €400,000 thousand, to further support its growth. The renewed facility consists of:
i.€170,000 thousand used to settle the old facility;
ii.up to €200,000 thousand to be used for financing and refinancing certain capital expenditures and permitted acquisitions (and for other permitted debt servicing uses); and
iii.up to €30,000 thousand to be used for issuance of guarantees and letters of credit (and when utilized by way of letters of credit, for general corporate purposes).
The renewed facility expires in December 2027 and bears interest at EURIBOR plus a margin. The principal terms and conditions of the renewed facility are as follows:
•drawdown stop when conditions precedent are not met;
•repayment in full at maturity date;
•commitment fee per year equals to 35% of the applicable margin and is payable for each undrawn facility in the period from the agreement signing date to the date being 42 months following the signing date. For the nine months ended September 30, 2023, the commitment fee was 1.365% per year (equal to 35% of the margin of 3.9%).
In December 2022, the Group completed two drawdowns on the renewed facility for a total amount of €279,210 thousand, of which €170,000 thousand was used to repay the Group’s old facility by a way of netting with the drawdown on the renewed facility. In June 2023, the Group completed an additional drawdown on the renewed facility of €43,400 thousand bringing the total drawdowns of the facility to €322,610 thousand.
In parallel to the renewed facility, the Group entered into two interest rate caps to hedge the interest rate risk on between 65% and 74% (2022: between 65% and 85%) of the outstanding loan amounts under the renewed facility. Details about the Group’s interest rate caps are included Note 16.
The refinancing of the old facility was accounted for as extinguishment of the former financial liability and recognition of the new debt instrument. Details about the accounting treatment are included in Note 25 of the consolidated financial statements for the year ended December 31, 2022.
Assets pledged as security
The renewed facility is secured by pledges on the bank accounts (presented as part of cash and cash equivalents and non-current other financial assets), trade and other receivables and pledges on the shares in the capital of Allego Holding B.V., Allego B.V., Allego GmbH and Allego France SAS held by the Company.
During the nine months ended September 30, 2023, the Group has pledged additional assets in relation to the renewed facility as detailed in the table below.
F-25

The carrying amount of assets pledged as security for the renewed facility is as follows:
(in €‘000)September 30,
2023		December 31,
2022
Current assets
Floating charge
Cash and cash equivalents6,543 56,317 
Trade receivables8,480 — 
Total current assets pledged as security15,023 56,317 
Non-current assets
Floating charge
Non-current other financial assets10,500 10,500 
Total non-current assets pledged as security10,500 10,500 
Total assets pledged as security25,523 66,817 
Transaction costs
During the period ended September 30, 2023, the Group incurred €1,689 thousand (September 30, 2022: €nil) of transaction costs that are directly attributable to the renewed facility. These costs are included in the measurement of the respective drawdowns and are amortized over the term of these drawdowns using the effective interest method. Interest expense on the Group’s renewed facility is recognized as part of finance income/(costs) in the interim condensed consolidated statement of profit or loss.
The Group expects that it will draw on the funds available under the renewed facility. Therefore, commitment fees paid on the unused portion of the renewed facility are deferred and treated as an adjustment to the loan’s effective interest rate and recognized as interest expense over the term of the facility.
Loan covenants
Under the terms of the renewed facility, the Group is required to comply with the following financial covenants related to interest and earnings before interest, taxes, depreciation and amortization (“EBITDA”) at the consolidated level of the Group:
1.Leverage ratio: calculated on a consolidated level as (total net debt / Group EBITDA).
2.Interest cover ratio: calculated on a consolidated basis as (Group EBITDA / interest paid).
The covenants shall be determined based on the IFRS financial statements of the Group, as required by the terms and conditions of the renewed facility. The compliance with these covenants shall be tested every six months, with the testing period being twelve months ending December 31 and June 30, with the first testing date being June 30, 2023.
The target covenant ratios are determined based on a twelve-month running basis and are as follows:

Testing period ending onLeverage ratioInterest cover ratio
June 30, 2023Unconditional
-0.8x
December 31, 2023Unconditional
-0.9x
June 30, 2024
33.9x
0.4x
December 31, 2024
5.4x
2.3x
June 30, 2025
3.2x
3.8x
December 31, 2025
2.2x
5.5x
June 30, 2026
2.2x
5.5x
December 31, 2026
2.2x
5.5x
June 30, 2027
2.2x
5.5x
F-26

The Group may within ten business days from the occurrence of a breach or the anticipated breach of the loan covenants remedy such default by providing evidence of receipt of new funding, sufficient to cure such breach (“equity cure right”). Such remediation is available for not more than two consecutive testing dates and four times over the duration of the renewed facility. In case if the covenants breach is not cured, such a breach is considered a default and could lead to the cancellation of the total undrawn commitments and the loan to become immediately due and payable.
Additionally, the following ratios are set as drawstop event conditions for the part of the renewed facility aimed at financing and refinancing certain capital expenditures and permitted acquisitions, which if breached prior to the anticipated utilization of the capex portion of the renewed facility – will result in the drawdown stop:
•Group EBITDA margin ratio: calculated on a consolidated level as (Group EBITDA / Real Period Revenue).
•Group EBITDA amount: calculated on a consolidated level
•Fast/ultra-fast charging equipment utilization rate: calculated on a consolidated level as (average number of sessions over the relevant Group charger base, divided by 50).
The target drawdown stop conditions are determined based on a twelve-month running basis and are as follows:
Testing period ending onEBITDA margin (drawstop)EBITDA (drawstop)Fast/ultrafast charging equipment utilization rate (drawstop)
June 30, 2023-4.3 %€(8.5) million10.4 %
December 31, 2023-5.8 %€(11.6) million11.5 %
June 30, 20248.1 %€19.8  million12.7 %
December 31, 202419.4 %€68.2  million12.9 %
June 30, 202524.1 %€111.2  million14.2 %
December 31, 202527.3 %€157.5  million15.5 %
June 30, 202628.9 %€200.0  million16.6 %
December 31, 2026UnconditionalUnconditionalUnconditional
June 30, 2027UnconditionalUnconditionalUnconditional

Breaching the requirements would cause a drawdown stop. Continuing breaches in the drawstop conditions would permit the bank to cancel the total undrawn commitments. The Group may within twenty business days from the occurrence of a drawstop event provide a remedial plan setting out the actions, steps and/or measures (which may include a proposal for adjustments of the financial covenants' or utilization rate's levels) which are proposed to be implemented in order to remedy such drawstop event.
In the preparation of its interim condensed consolidated financial statements, the Group assessed whether information about the existence of the covenant and its terms is material information, considering both the consequences and the likelihood of a breach occurring. The consequences of a covenant breach have been described in this note. A covenant breach would affect the Group’s financial position and cash flows in a way that could reasonably be expected to influence the decisions of the primary users of these interim condensed consolidated financial statements. Refer to Note 2.2 for additional information.
The Group has complied with these covenants in the reporting period ended September 30, 2023.
14    Income tax
The income tax expense for the nine months ended September 30, 2023 is recognized based on the Group’s estimate of the weighted average effective annual income tax rate expected for the full financial year. The estimated average annual tax rate used for the nine months ended September 30, 2023 is 0.38% (nine months ended September 30, 2022: 0.36%).
F-27

15    Financial instruments
This note provides information about the Group’s financial instruments, including:
•an overview of all financial instruments held by the Group;
•the classification of the financial instruments;
•the line item on the interim condensed consolidated statement of financial position in which the financial instrument is included;
•the financial instrument’s book and fair value.
The Group holds the following financial instruments:
Financial assets
(in €‘000)NotesAt amortized
cost		Fair value
through
PL		Fair value
through
OCI		Total book
value		Total fair
value
As at December 31, 2022
Non-current other financial assets21,900 9,198 31,389 62,487 62,487 
Current other financial assets601 — — 601 601 
Trade and other receivables44,776 — — 44,776 44,776 
Cash and cash equivalents83,022 — — 83,022 83,022 
Total150,299 9,198 31,389 190,886 190,886 
As at September 30, 2023
Non-current other financial assets22,439 8,603 29,463 60,505 60,505 
Current other financial assets6,469 — — 6,469 6,469 
Trade and other receivables36,639 — — 36,639 36,639 
Cash and cash equivalents28,829 — — 28,829 28,829 
Total94,376 8,603 29,463 132,442 132,442 
Due to the highly liquid nature of cash and cash equivalents and the pledged bank balances classified within non-current other financial assets, their carrying amount is considered to be the same as their fair value. Due to the short-term nature of trade and other receivables as well as current other financial assets, their carrying amount is considered to be the same as their fair value.
F-28

Financial liabilities
(in €‘000)NotesAt amortized
cost		Fair value through PLTotal book
value		Total fair
value
As at December 31, 2022
Borrowings13269,033 — 269,033 272,641 
Non-current lease liabilities44,044 — 44,044 N/A
Current lease liabilities7,280 — 7,280 N/A
Trade and other payables51,263 — 51,263 51,263 
Warrant Liabilities— 1,296 1,296 1,296 
Total371,620 1,296 372,916 325,200 
As at September 30, 2023
Borrowings13312,160 — 312,160 325,409 
Non-current lease liabilities60,212 — 60,212 N/A
Current lease liabilities9,279 — 9,279 N/A
Trade and other payables51,640 — 51,640 51,640 
Warrant liabilities— 5,471 5,471 5,471 
Total433,291 5,471 438,762 382,520 
Due to the short-term nature of the trade and other payables, their carrying amount is considered to be the same as their fair value.
16    Fair value measurement
This note explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value and the financial instruments for which the fair value is disclosed in the interim condensed consolidated financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards.
An explanation of each level is included in Note 2.7.18 of the consolidated financial statements for the year ended December 31, 2022.
Assets and liabilities measured at fair value
As at September 30, 2023, the Group has recorded the following financial instruments at fair value in the interim condensed consolidated statement of financial position:
•interest rate cap derivatives;
•warrant liabilities;
•investment in equity securities.
Interest rate cap derivatives and the investment in equity securities are presented within non-current other financial assets. Warrant liabilities are presented as a separate line in the interim condensed consolidated statement of financial position as at September 30, 2023.
The interest rate caps qualify for the level 2 category in the fair value hierarchy due to the fact that they are not traded in an active market and the fair value is determined using valuation techniques which maximize the use of observable market data. Since all significant inputs required to fair value the instruments are observable, the instruments are included in level 2.
The investment in equity securities qualifies for the level 3 category in the fair value hierarchy due to the fact that the securities are not traded in an active market and there is no observable market data. Therefore, the fair value of these securities is determined using valuation techniques which use unobservable inputs that are significant to fair value.
The warrants qualify for the level 1 category in the fair value hierarchy due to the fact that their fair value is determined based on quoted market inputs.
F-29

For assets and liabilities that are recognized in the interim condensed consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. During the nine months ended September 30, 2023, there were no transfers that occurred between levels.
The fair values of the Group’s assets and liabilities measured at fair value are disclosed in the table in Note 15.
Fair value of assets and liabilities not measured at fair value
The Group has determined the fair value of assets and liabilities not measured at fair value, but for which the fair value is required to be disclosed.
Borrowings:
For the renewed facility, the fair value differs from its carrying amount because the interest payable on the facility is (partially) fixed. The borrowings qualify for the level 3 category in the fair value category due to the use of unobservable inputs, including own credit risk.
The fair values of the Group’s assets and liabilities not measured at fair value are disclosed in the table in Note 15.
Specific valuation techniques to determine fair values
Specific valuation techniques used to value financial instruments include:
•interest rate cap derivatives: option pricing model;
•investment in equity securities: discounted cash flow analysis;
•borrowings: discounted cash flow analysis using a market interest rate;
Financial instruments measured at fair value (level 3)
The changes in level 3 items for the nine months ended September 30, 2023 have been as follows:
(in €‘000)Investment in equity securities
Carrying amount at January 1, 202331,389 
Movements in the nine months ended September 30, 2023
Fair value loss on investment in equity securities recognized in other comprehensive income(1,926)
Carrying amount at September 30, 202329,463 
The Group’s engages with third party valuation specialists to perform its fair value measurements for financial reporting purposes on a periodic basis. Involvement of external valuers is determined annually by the Group’s finance team after discussion with and approval by the Group’s Executive Board. Selection criteria for valuation specialist include market knowledge, reputation, independence and whether professional standards are maintained.
The Group works closely with the qualified external valuers to establish the appropriate valuation techniques and inputs to the model. At each reporting date, the Group analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Group’s accounting policies.
Valuation inputs to the fair value of investments in equity securities
The Group updated the third party valuation report to determine the fair value of investments in equity securities. Inputs to the fair value of the investments in equity securities are the earnings growth factor and risk-adjusted discount rate. The following table summarizes the quantitative information about the significant unobservable input parameters used in the
F-30

level 3 fair value measurement of the investments in equity securities, using the DCF (“Discounted Cash Flows”) methodology.
In %September 30, 2023
Growth factor3.0 %
Discount rate11.9 %
An increase or decrease of 100 basis point in the growth factor would change the fair value of the investment in equity by an increase of €3,741 thousand or a decrease of €2,984 thousand, respectively.
An increase or decrease of 100 basis point in the discount rate would change the fair value of the investment in equity by a decrease of €4,187 thousand or an increase of €5,255 thousand, respectively.
17    Financial risk management
This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance.
RiskExposure arising fromMeasurementManagement
Market risk – interest rate riskLong-term borrowings at variable ratesSensitivity analysisEconomic hedge with an interest rate caps
Market risk – price riskInvestments in equity securitiesSensitivity analysisMonitoring quarterly valuation updates and forecasts of future cash flows
Liquidity riskBorrowings and other liabilitiesCash flow forecastsAvailability of borrowing facilities.
The Group’s management oversees the management of these risks. The Group’s management is supported by the Finance department that advises on financial risks and the appropriate financial risk governance framework for the Group. The Group’s risk management is predominantly controlled by the Finance department under policies approved by the Executive Board. The Executive Board provides principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments. Since the largest part of the Group’s assets, liabilities, and transactions are denominated in euro, the market risk of foreign exchange is considered not to be significant. There are no changes compared to the previous period.
Market risk
Cash flow and fair value interest rate risk
The Group’s main interest rate risk arises from a long-term borrowing with a variable rate, which exposes the Group to cash flow interest rate risk. The cash flow risk is mitigated through the usage of interest rate caps. During the nine months ended September 30, 2023 and 2022, the Group’s borrowings at a variable rate were denominated in euro.
The Group’s borrowings are carried at amortized cost.
Instruments used by the Group
The Group has two interest rate caps in place with a notional of €237,458 thousand (December 31, 2022: two interest rate caps with a notional of €181,487 thousand) which mature in December 2027 (December 31, 2022: in December 2027). As at September 30, 2023, the interest rate caps cover approximately 74% (December 31, 2022: 65%) of the variable loan principal outstanding. The strike price changes over time and ranges between 1.50% and 3.43%. The interest rate caps mitigate between 65% and 74% (December 31, 2022: between 65% and 85%) of the variable debt outstanding, as the notional of the derivative instruments and the renewed facility changes over time. The remaining cash flow risk is accepted.
The interest rate caps require settlement of any interest receivable, if applicable, semiannually. The settlement dates coincide with the dates on which interest is payable on the renewed facility.
F-31

Sensitivity
The interim condensed consolidated statement of profit or loss is sensitive to higher/lower interest expenses from borrowings as a result of changes in interest rates as both the Group’s old and renewed facilities have a variable interest rate. Equity is not impacted as no hedge accounting is applied. Additionally, an increase or decrease of the Euribor has an impact on the fair value of the Group’s interest rate caps.
The impact on loss for the three and nine months ended September 30, 2023 and 2022 as a result of a change in interest rates is as follows:

(in €‘000)Impact on pre-tax loss
For the three months ended September 30,For the nine months ended September 30,
2023202220232022
Interest rates – increase by 10 basis points*
5 31 463 258 
Interest rates – decrease by 10 basis points*
(4)(38)(439)(253)
*Keeping all other variables constant.
Global regulators and central banks have been driving international efforts to reform key benchmark interest rates. The market is therefore in transition to alternative risk-free reference rates. Although limited impact is expected on the Euribor, the Group is in the process of evaluating the implications of such a phase out. The Group has no interest rate hedging relationships which are affected by the reform and does not expect any significant impact on existing contracts due to a change in the interest rates. The Group will continue to monitor market developments.
Price risk
Exposure
The Group’s exposure to equity securities price risk arises from investments held by the group and classified in the interim condensed consolidated statement of financial position as at fair value through other comprehensive income ("FVOCI") as detailed in Note 19 of the consolidated financial statements for the year ended December 31, 2022. The price risk is mitigated by monitoring quarterly valuation updates and forecasts of future cash flows and aligning the business strategy accordingly.
Sensitivity
The table below summarizes the impact of increases/decreases of the price of equity securities on the group’s equity through OCI reserve for the period. The analysis is based on the assumption that the fair value of the equity securities held by the group has increased or decreased by 40%, with all other variables held constant.
(in €‘000)Impact on Group's Equity
For the nine months ended September 30,
Fair Value – increase by 4,000 basis points
11,785 
Fair Value – decrease by 4,000 basis points
(11,785)
Liquidity risk
Prudent liquidity risk management implies maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due and to close out market positions. Due to the dynamic nature of the underlying businesses, the Group maintains flexibility in funding by maintaining availability under committed credit lines. The Group has been predominantly contracting customers of sound commercial standing and their payment behavior was generally good. Refer to Note 2.2 for details about the Group’s financial position and the going concern assumption applied in preparing the interim condensed consolidated financial statements.
As disclosed in Note 13, the Group has pledged bank balances to secure the payment of interest and commitment fees to the Group’s external lenders and pledged bank balances in relation to bank guarantees issued to suppliers of the Group.
The main risk for the Group is not meeting the debt covenants or drawdown requirements described in Note 13. In this case, funding via the renewed facility would not be available. The Group monitors the liquidity risk on a weekly basis.
F-32

Management monitors rolling forecasts of the Group’s cash and cash equivalents on the basis of expected cash flows. This is generally carried out at Group level, in accordance with practice and limits set by the Group. In addition, the Group’s liquidity management policy involves projecting cash flows and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans. The Group assessed the concentration of risk with respect to refinancing its debt and concluded it to be low.
Financing arrangements
The Group had access to the following undrawn borrowing facilities for each reporting period presented:
(in €‘000)September 30, 2023December 31, 2022
Expiring beyond one year—renewed facility77,390 120,790 
The renewed facility is available to be drawn if the drawdown covenants are met, in euros and has an average maturity of approximately 4 years (December 31, 2022: 5 years).
18    Commitments and contingencies
Purchase commitments for chargers and charging infrastructure
Significant expenditures for chargers and charging infrastructure contracted for, but not recognized as liabilities, as at September 30, 2023 were €18,974 thousand (December 31, 2022: €2,452 thousand). The Group uses these assets either as own chargers (property, plant and equipment) or as charging equipment to fulfill its obligations under development contracts entered into with its customers (inventory). As a result of the additional liquidity obtained from the renewed facility in December 2022, and in line with the growth strategy and business plan of the Group, the company has been increasing its level of commitment towards capital expenditures and inventory purchases during the nine months ended September 30, 2023.
Purchase commitments for renewable electricity
As disclosed in Note 2.2, Allego has entered into medium- and long-term power purchase agreements with renewable power producers. Significant expenditures for renewable electricity and corresponding CO2 tickets contracted for, but not recognized as liabilities, as at September 30, 2023 were €233,149 thousand (December 31, 2022: €69,701 thousand).
19    Related-party transactions
Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Group and other related parties are disclosed below.
Terms and conditions of transactions with related parties
Management services were bought from the immediate parent entity for a fixed fee. All other transactions were made on normal commercial terms and conditions and at market rates. Outstanding balances are unsecured. Asset and liability positions can either be offset or can be settled in cash. No loss allowance is recognized on these balances.
F-33

19.1. Transactions with related parties

For the three months ended September 30,For the nine months ended September 30,
(in €‘000)Relationship2023202220232022
Madeleine Charging B.V.Immediate
parent entity
Interest expenses on shareholder loans— — — 1,755 
Management fee— — — 12 
Reimbursement of advisory fees— — — 280 
Share-based payment expenses— — — 74,001 
Mega-E Group (Mega-E Charging B.V. and its subsidiaries)Other related party
Revenue from contracts with related party— — — 1,474 
EV CarsOther related party
Revenue from contracts with related party3,205 4,482 12,311 22,826 
VoltalisOther related party
Revenue from contracts with related party1,364 989 4,091 1,279 
Madeleine Charging B.V
For the three months ended September 30, 2023, transactions with Madeleine amounted to € nil (three months ended September 30, 2022 : € nil). For the nine months ended September 30, 2023, transactions with Madeleine amounted to € nil (nine months ended September 30, 2022: €76,048 thousand). The change is largely driven by the SPAC Transaction, which occurred on March 16, 2022.
On March 16, 2022, immediately prior to the closing of the SPAC Transaction, the outstanding principal of the shareholder loans together with the accrued interest on these loans with Madeleine was converted into equity. As a result no further interest expenses related to these shareholder loans were incurred by the Group (Refer to Note 25 of the consolidated financial statements for the year ended December 31, 2022).
Prior to the SPAC Transaction, Allego was required to pay Madeleine management fees and reimburse advisory fees, which are no longer applicable From March 16, 2022 as a result of the SPAC Transaction.
Share-based payment expenses with Madeleine related to the First Special Fees Agreement and the Second Special Fees Agreement. The First Special Fees Agreement was terminated prior and in connection with the SPAC Transaction and no further share-based payment expenses with Madeleine were incurred in relation to it after March 16, 2022 (Refer to Note 11.1 of the consolidated financial statements for the year ended December 31, 2022). The Second Special Fees Agreement was novated from Madeleine to Allego on April 20, 2022 and no further share-based payment expenses were incurred from that date in relation to Madeleine (refer to note 7.1 for details on the Second Special Fees Agreement).
Mega-E Group
The transactions with Mega-E until March 16, 2022, are considered related-party transactions. The Group obtained control of Mega-E as of that date. All subsequent transactions are therefore considered to be intra-group transactions and have been eliminated in these interim condensed consolidated financial statements.
F-34

20    Subsequent events
The following subsequent events occurred after September 30, 2023:
Public warrants exchange
As at September 30, 2023, the Group had 13,799,948 public warrants outstanding and no private placement warrants. On October 3, 2023, the Group announced the completion of its previously announced exchange offer (dated August 25, 2023) and consent solicitation relating to its outstanding public warrants. On October 3, 2023, the Company issued 2,996,918 ordinary shares in exchange for the 13,029,838 public warrants tendered in the exchange offer. The remaining 770,110 public warrants were exchanged for 159,712 ordinary shares, effective October 18, 2023. No consideration was received from the Company as part of the exchange. As a result of these transactions, no public warrants remain outstanding.
Guarantee facility
On December 19, 2022, the Group has entered into a renewed facility agreement with a group of lenders led by Société
Générale and Banco Santander, which included up to €30,000 thousand to be used for issuance of guarantees and letters of credit. The first letters of credit were issued on October 19, 2023 to Solarpark Lindenhof GmbH, as follows: one letter of credit from Banco Santander for the maximum original amount of €6,250 thousand and one letter of credit from Société
Générale for the maximum original amount of €6,250 thousand.
F-35